Apellis EU Medical Hub
  • Science
    • Geographic Atrophy
    • Pipeline
  • Medical Research
    • Scientific Focus
    • Investigator Initiated Trials
    • Collaborative Research
    • Medical Writing Grants
  • Congress & Manuscripts
    • Congress Presentations
    • Manuscripts
  • Resources
    • Medical Information
  • This website is intended only for use by Healthcare Professionals licensed to practice in Europe.

  • Menu Menu
  • Science
    • Geographic Atrophy
    • Pipeline
  • Medical Research
    • Scientific Focus
    • Investigator Initiated Trials
    • Collaborative Research
    • Medical Writing Grants
  • Congress & Manuscripts
    • Congress Presentations
    • Manuscripts
  • Resources
    • Medical Information
  • This website is intended only for use by Healthcare Professionals licensed to practice in Europe.

Home / Congress Presentations / Geographic Atrophy / RWC 2022

Efficacy and safety of intravitreal pegcetacoplan in geographic atrophy: results from the Phase 3 OAKS and DERBY trials

Share Via Email

The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.

Report an Adverse Event or Product complaint

Please call +1 833-866-3346

Ask a Medical Question

Please click here or email medinfo@apellis.com

Connect with an MSL

Set up a meeting with your
Medical Science Liaison

Privacy PolicyTerms and ConditionsImprint

©2024 Apellis International GmbH. All rights reserved. Jan 2024 MED-EU-PEGGA-23-00016 v2.0
Scroll to top
You are now leaving ApellisMedicalHub.eu

You are about to leave ApellisMedicalHub.eu to visit a third-party website. We recommend reviewing the privacy policy and terms & conditions of any site you visit, as Apellis International GmbH is not responsible for their content.

I agree